Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells.
作者： Tao You , Weiguo Hu , Xiaowen Ge , Jingnan Shen , Xuebin Qin
DOI: 10.1038/CMI.2010.35
关键词:
摘要: Many monoclonal antibodies (mAbs) have been extensively used in the clinic, such as rituximab to treat lymphoma. However, resistance and non-responsiveness mAb treatment challenging for this line of therapy. Complement is one main mediators antibody-based cancer therapy via complement-dependent cytolysis (CDC) effect. CD59 plays a critical role mAbs through CDC In paper, we attempted investigate whether novel inhibitor, recombinant ILYd4, was effective enhancing rituximab-mediated effect on rituximab-sensitive RL-7 lymphoma cells rituximab-induced resistant RR51.2 cells. Meanwhile, effects, which were mediated by anti-CD24 mAb, refractory multiple myeloma (MM) cell ARH-77 solid tumor osteosarcoma Saos-2, respectively investigated. We found that rILYd4 rendered sensitive mAb-mediated exhibited synergistic with resulted lysis. This lysis apparent both hematological tumors tumors. Therefore, may serve an adjuvant mediated-tumor immunotherapy.
nature.com
sci-hub.se 参考文章(45)
Josée Golay, Luisella Zaffaroni, Thomas Vaccari, Manuela Lazzari, Gian-Maria Borleri, Sergio Bernasconi, Francesco Tedesco, Alessandro Rambaldi, Martino Introna, Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood. ,vol. 95, pp. 3900- 3908 ,(2000) , 10.1182/BLOOD.V95.12.3900
David M. Loeb, Is There a Role for Immunotherapy in Osteosarcoma Cancer treatment and research. ,vol. 152, pp. 447- 457 ,(2009) , 10.1007/978-1-4419-0284-9_25
Noopur Raje, Kenneth C. Anderson, Steven P. Treon, Immunotherapeutic strategies for the treatment of plasma cell malignancies. Seminars in Oncology. ,vol. 27, pp. 598- 613 ,(2000)
Andrew L. Harris, B. Paul Morgan, Complement Regulatory Proteins ,(1999)
Weiguo Hu, Qigui Yu, Ningjie Hu, Daniel Byrd, Tohti Amet, Cecilia Shikuma, Bruce Shiramizu, Jose A. Halperin, Xuebin Qin, A High-Affinity Inhibitor of Human CD59 Enhances Complement-Mediated Virolysis of HIV-1: Implications for Treatment of HIV-1/AIDS The Journal of Immunology. ,vol. 184, pp. 359- 368 ,(2010) , 10.4049/JIMMUNOL.0902278
Rossen M. Donev, Lisa C. Gray, Baalasubramanian Sivasankar, Timothy R. Hughes, Carmen W. van den Berg, B. Paul Morgan, Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma Cancer Research. ,vol. 68, pp. 5979- 5987 ,(2008) , 10.1158/0008-5472.CAN-07-6828
Line Bjørge, Juha Hakulinen, Torsten Wahlström, Roald Matre, Seppo Meri, Complement-regulatory proteins in ovarian malignancies. International Journal of Cancer. ,vol. 70, pp. 14- 25 ,(1997) , 10.1002/(SICI)1097-0215(19970106)70:1<14::AID-IJC3>3.0.CO;2-9
Jorge Castillo, Cannon Milani, Daniel Mendez-Allwood, Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders Expert Opinion on Investigational Drugs. ,vol. 18, pp. 491- 500 ,(2009) , 10.1517/13543780902832679
Yuxiang Huang, Alena Fedarovich, Stephen Tomlinson, Christopher Davies, Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex. Acta Crystallographica Section D-biological Crystallography. ,vol. 63, pp. 714- 721 ,(2007) , 10.1107/S0907444907015557
Martin J. Glennie, Ruth R. French, Mark S. Cragg, Ronald P. Taylor, Mechanisms of killing by anti-CD20 monoclonal antibodies. Molecular Immunology. ,vol. 44, pp. 3823- 3837 ,(2007) , 10.1016/J.MOLIMM.2007.06.151